On May 14, 2020 Abivax announced it had received clearance from Franceﾒs National Agency for the Safety of Medicines and French Ethics Committee to initiate a randomized, double-blind, placebo-controlled Phase 2b/3 trial of ABX464 to prevent severe inflammation that leads to acute respiratory distress syndrome (ARDS) in 1,034 COVID-19 elderly or high-risk patients (miR-AGE trial).